XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants
S. Jain, S. Kumar, L. Lai, S. Linderman, A. A. Malik, M. L. Ellis, S. Godbole, D. Solis, M. K. Sahoo, K. Bechnak, I. Paredes, R. Tanios, B. Kazzi, S. M. Dib, M. B. Litvack, , M. S. Suthar
The paper evaluates the effectiveness of an XBB.1.5 monovalent booster vaccine, showing improved antibody binding and neutralization against SARS-CoV-2 Omicron variants.
bioRxiv · Feb 3, 2024 · PreprintImmunology